Johnson and Johnson’s Innovation Center will fund early R&D efforts for one of drug startup Alector’s targets, with the option to negotiate a commercial agreement if the startup can show proof of concept.
Alector is based at the Janssen Labs @QB3 innovation lab in San Francisco. The specifics about the monoclonal antibody being developed have not been disclosed, but the early stage exploratory program has potential to enhance J&J's Alzheimer’s pipeline.
Read more at Med City News